Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–64 of 64 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Florbetapir Clear all
Completed No phase listed Observational

Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials

NCT02918539
View directory record Official record
Conditions
Alzheimer Disease, Cognition Disorders
Interventions
florbetapir F 18 PET scan
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
75
States / cities
Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 3, 2026, 6:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss

NCT03587649
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Healthy Volunteers
Interventions
[18F]MNI-1126
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 3, 2026, 6:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study

NCT01834716
View directory record Official record
Conditions
Alzheimer's Disease Prevention
Interventions
Aerobic vs. Non-Aerobic exercise
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 3, 2026, 6:51 PM EDT
Terminated No phase listed Observational

Prognostic Value of Aβ Imaging in NPH Prior to Shunt Placement

NCT01834625
View directory record Official record
Conditions
Normal Pressure Hydrocephalus Patients
Interventions
PET scan
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 3, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

NCT00857415
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 3, 2026, 6:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease

NCT02370524
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
[18F]T807
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
20 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 3, 2026, 6:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 18F-AV-45 in Healthy Volunteers

NCT01564706
View directory record Official record
Conditions
Alzheimer Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Jenkintown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 3, 2026, 6:51 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol

NCT07012993
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia, Healthy Volunteers
Interventions
18F-Florbetapir or 18F-Flutemetamol
Drug
Lead sponsor
Akiva Mintz
Other
Eligibility
18 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 3, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

NCT01400425
View directory record Official record
Conditions
Progressive Cognitive Decline
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 3, 2026, 6:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers

NCT03902548
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F]P16-129
Drug
Lead sponsor
Five Eleven Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 3, 2026, 6:51 PM EDT
Terminated Phase 4 Interventional Results available

The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

NCT03040427
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
F-18 florbetapir
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 3, 2026, 6:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers

NCT01826110
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
[11C]PIB
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 3, 2026, 6:51 PM EDT
Active, not recruiting Phase 4 Interventional

Effects of Brain Beta-Amyloid on Postoperative Cognition

NCT01606488
View directory record Official record
Conditions
Postoperative Cognitive Dysfunction
Interventions
Florbetapir F 18 (18F-AV-45), no intervention
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 3, 2026, 6:51 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)

NCT07843459
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid, Plasma
Interventions
LY4560736, Placebo, Florbetapir F18, Florbetaben F 18
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
13
States / cities
Anaheim, California • Irvine, California • Los Alamitos, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 3, 2026, 6:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

NCT03545789
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease, Progressive Supranuclear Palsy
Interventions
[18F]MNI-958
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 3, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

NCT01518374
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
Interventions
Florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,768 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
26
States / cities
Phoenix, Arizona • Sun City, Arizona • Davis, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 3, 2026, 6:51 PM EDT